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Abstract: Chemotherapy-induced nausea and vomiting and postoperative nausea and 
vomiting are one of the most frequent but also very concerning consequences for patients 
undergoing chemotherapy or surgical procedures under general anesthesia. There are a variety 
of mechanisms involved in the activation of nausea and vomiting. Serotonin, a ubiquitous central 
and peripheral neurotransmitter, is thought to be the predominant mediator of the perception 
of nausea and triggering of the vomiting response in both the brain and the periphery via the 
5-hydroxytryptamine type 3 (5-HT3) receptor pathways. 5-HT3 receptor antagonists disrupt this 
pathway, largely at the level of the vagal afferent pathways, to decrease nausea and vomiting. 
This review will focus on dolasetron, an older but sill commonly used 5-HT3 receptor antagonist 
and its multimodal mechanism of action, safety and tolerability, patient considerations, and a 
review of the current literature on its use to combat both chemotherapy-induced and postoperative 
nausea and vomiting in these two important patient populations.
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Background
Over 1.5 million patients are diagnosed with cancer each year in the United States.1 
Many of these individuals will undergo chemotherapy for their disease; however, 
the consequences and side effects of the treatment are feared by many. Of these 
side effects, chemotherapy-induced nausea and vomiting (CINV) is one of the most 
concerning adverse effects for patients initiating treatment, even more so than the 
associated alopecia.2 Overall, up to 70%–80% of patients undergoing chemotherapy 
may experience emesis.3 CINV may be a precipitating factor in patients abandoning 
therapy, with a potential negative impact on outcomes.4 Aside from patient satisfaction, 
uncontrolled CINV may result in malnutrition, dehydration, weight loss, and electrolyte 
imbalances, and could lead to several types of complications, such as fractures, 
esophageal tears, and wound dehiscence.2,3 Clearly, reduction of this significant side 
effect improves quality of life for patients undergoing chemotherapy. The knowledge 
that their adverse effects can be effectively managed may encourage more individuals 
to undergo therapy and potentially improve their outcomes dramatically.
Likewise, more than 40 million surgeries are performed per year in the United 
States.5 Of this large number, nearly one-third of patients experience postoperative 
nausea and vomiting (PONV).6 PONV is one of the most commonly reported adverse 
effects of anesthesia. Even patients with zero known risk factors carry a 10% risk of 
PONV . This risk increases dramatically to 61% and 79%, respectively, when 3 or 4 
risk factors exist (female gender, nonsmoker, history of motion sickness, postoperative 
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opioid use, and a history of PONV). Much like CINV, 
PONV may have significant detrimental effects on surgical 
outcome, including aspiration, wound dehiscence, and 
esophageal rupture.7,8 PONV prophylaxis is an extremely 
common perioperative practice, even in patients without risk 
factors for PONV due to the potential adverse outcomes and 
increased cost of care when PONV is inadequately controlled. 
5-Hydroxytryptamine type 3 (5-HT3) receptor antagonists are 
generally a mainstay of this practice and are administered 
many times each day in the operating room.
Serotonin, a ubiquitous central and peripheral neu-
rotransmitter, is thought to be the predominant mediator 
of the perception of nausea and triggering of the vomiting 
response in both the brain and the periphery via the 5-HT3 
receptor pathway.8 Though these receptors are present in 
the area postrema, which is the chemoreceptor trigger zone 
for vomiting in the brain, the evidence suggests that the 
predominant site of action for 5-HT3 receptor antagonists is 
in the peripheral vagal afferents (Figure 1). High concentra-
tions of serotonin are found in the enterochromaffin cells of 
the gut. Toxins, such as chemotherapy, can trigger release 
of serotonin from these cells, with subsequent activation of 
5-HT3 receptors in vagal afferent pathways which synapse 
in the nucleus tractus solitarius in the medulla. This, in turn, 
activates efferent pathways to cause the act of vomiting.3,8 
5-HT3 receptor antagonists disrupt this pathway, largely at 
the afferent vagal level, to decrease nausea and vomiting.3 
This paper will focus on dolasetron, a commonly used 5-HT3 
receptor antagonist, and its multimodal mechanism of action, 
safety and tolerability, patient considerations, and a review 
of the current literature on its use to combat both CINV and 
PONV in these two important patient populations.
Pharmacology and 
pharmacokinetics of dolasetron
Peripheral serotonin acts on multiple subtypes of 5-HT 
receptors throughout the peripheral nervous system. The 
primary serotonin receptor involved in the emesis pathway 
is the 5-HT3 receptor.3 The 5-HT3 receptor is a ligand-gated 
ion channel present on the abdominal vagal afferents which, 
when activated, initiates a cascade of signals throughout 
the central nervous system to cause the sensation of nausea 
and the act of vomiting via multiple efferent pathways.3,9 
  Dolasetron mesylate is a pseudopelletierine-derived pure 
5-HT3 antagonist which acts to suppress the sensation 
of nausea and the vomiting response.8,9 Dolasetron has 
a short elimination half-life of 0.13–0.24 hours and is 
  rapidly converted by carbonyl reductase to its active form, 
 hydrodolasetron, which has an approximately 50-fold 
higher affinity for the 5-HT3 receptor.7–9 Hydrodolasetron 
reaches its peak plasma concentration at 0.5–0.6 hours and 
has a mean plasma elimination half-life of 4–8 hours when 
administered intravenously. These characteristics give 
dolasetron an extended duration of action beyond that of 
ondasetron, the novel 5-HT3 antagonist. When administered 
orally, it reaches its peak plasma concentration at one 
hour and has a plasma elimination half-life of 5–10 hours. 
Oral bioavailability ranges from 70%–89% depending 
on increasing age.9   Hydrodolasetron is predominantly 
conjugated with glucuronide and/or sulfate groups, as well as 
Figure 1 Schematic representation of the mechanisms of emesis associated with chemotherapy-induced and postoperative nausea and vomiting.
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oxidated with different forms of cytochrome P450 (CYP). 
The conjugated forms of hydrodolasetron are then excreted 
59% in the urine and 25% in the feces7,9 (Figure 2).
The metabolism of hydrodolasetron and most other 5-HT3 
receptor antagonists (with the notable exception of granis-
etron) is, in part, dependent on the CYP2D6 isoform system. 
Genetic polymorphism in the CYP2D6 isoform system is 
responsible for alterations in the rates of the metabolism of 
compounds which are inactivated by this system. This system 
is responsible for the metabolism of approximately 25% of all 
prescribed drugs; therefore, these polymorphisms may have 
a profound clinical impact in certain circumstances. More 
than 90 distinct alleles have been identified. Carriers of the 
polymorphic alleles can be classified, based on the metabolic 
rate of the reference compounds, as extensive metabolizers 
(wild-type), poor metabolizers, intermediate metabolizers, 
or ultrarapid metabolizers. These polymorphisms vary by 
population. For example, up to 10% of Caucasians, but 
less than 2% of Asians and African-Americans, show the 
poor metabolizer phenotype. Up to 20% of certain global 
populations exhibit the ultrarapid metabolizer phenotype. 
These variants may impact the efficacy of the drugs they 
metabolize.7,10
Dolasetron, for example, may have increased activity 
and duration of action in the poor metabolizer population, 
but may have markedly decreased efficacy in the ultrarapid 
metabolizer population. These polymorphisms could also 
impact the adverse effects of dolasetron, because these effects 
have been directly correlated with serum hydrodolasetron 
levels.11
Safety and tolerability of dolasetron
Since the development of the 5-HT3 receptor antagonists, the 
overwhelming majority of studies have found them to have 
a wide margin of safety and to be well tolerated.7 In fact, the 
consensus statement on postoperative nausea and vomiting 
prophylaxis published in 2003 reported that all 5-HT3 
receptor antagonists are “equally safe”.10 The most commonly 
reported adverse reaction to dolasetron is headache, with an 
incidence of up to 24%.9 Other commonly reported events 
are mild, and include diarrhea, fatigue, and dizziness.1,3,7,9 
However, limited, yet more recently published data suggest 
there may be evidence of significant cardiovascular events 
associated with administration of dolasetron.
Early data demonstrated the possibility of prolonged 
cardiac conduction intervals in both healthy volunteers 
and perioperative or chemotherapy patients; however, 
these changes were felt to be transient and not clinically 
significant.9 Trigg and Higa most recently published a review 
of the CINV literature in 2010 and found no or extraordinarily 
rare adverse cardiovascular events.1,3 However, there 
exists some limited evidence that even modest doses of 
dolasetron can be responsible for significant cardiovascular 
complications.
Dolasetron has been shown to slow cardiac depolarization 
by blocking fast sodium channels, thereby reducing maximum 
upstroke velocity of the action potential.12–14 This effect causes 
changes in multiple electrocardiographic parameters, including 
heart rate, PR interval, QRS duration and, at increased doses 
(2.4 mg/kg), the QTc interval.15 There is also evidence to 
suggest that many drugs, including dolasetron, also interact 
with potassium channels, thereby affecting repolarization.16 
QTc changes are generally considered to be due to a widened 
QRS and increases in heart rate; however, there are limited 
reports of true JT prolongation as well.11,12,17 These effects 
have been noted to be directly correlated with the serum 
hydrodolasetron concentrations and may persist for up to 
24 hours (the noted duration of therapeutic effect of a single 
dose of dolasetron).11,18,19 A thorough examination of the 
current literature will show that these reports are limited and 
similar to other drugs of the class.
Patient considerations regarding 
dolasetron
Given the aforementioned findings, particular consideration 
should be given to certain patient populations. Foremost, 
patients with a pre-existing history of widened QRS or 
prolonged QTc on electrocardiography should be particularly 
Figure 2 Metabolic pathways of dolasetron. 
Abbreviations: CYP2D6, cytochrome P450 2D6 isoform; CYP3A, cytochrome P450 3A isoform; Mx, metabolism.
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concerning, especially at the higher doses required for 
CINV (1.8–2.4 mg/kg). Up to 10%–30% of asymptomatic 
individuals may have a prolonged QTc at baseline.20 
Likewise, administration of dolasetron in patients known to 
be predisposed to unstable tachyarrhythmias should also be 
avoided. However, when choosing a replacement antiemetic, 
it should be noted that ondansetron has also been shown 
to induce arrhythmia and prolong QTc, though to a lesser 
extent than dolasetron.12,21–23 This is thought to be due to a 
blockade of potassium channels, which, in turn, prolongs 
repolarization.11 Palonosetron has also been shown to prolong 
QTc by as much as 3.4 msec at doses as low as 0.25 mg.24 
Based on this information, these patients would likely benefit 
from therapy outside the 5-HT3 receptor antagonist class.
Genetic variability may also play a role in identifying 
patients susceptible to significant adverse reactions to 
dolasetron and other 5-HT3 receptor antagonists. As 
previously mentioned, dolasetron is metabolized by the 
CYP2D6 pathway, which has been shown to exhibit genetic 
polymorphisms resulting in significant variability in rate 
of metabolism of substrates.7 Dolasetron, tropisetron, and 
palonosetron all share this common pathway, so this 
variability will not only affect their antiemetic properties, 
but may also exacerbate the adverse effects of these drugs. 
However, palonosetron is reported to be unaffected by poor 
or extensive metabolizers. Granisetron, on the other hand, is 
metabolized independent of the CYP2D6 pathway, so these 
polymorphisms do not affect its properties.10 Recent genetic 
data has also identified a single nucleotide polymorphism 
within the NOS1AP gene that may place patients at increased 
risk for developing prolonged QTc after 5-HT3 receptor 
antagonist administration.20 Further investigation into 
these polymorphisms may allow clinicians to individualize 
therapeutic regimens more precisely and to treat their patients 
more effectively. However, dose adjustments for dolasetron 
are currently unnecessary based on readily available 
information (age, renal function, and hepatic function).9
Renewed clinical data for dolasetron
Studies evaluating dose responsiveness have found a 
plateaued dose-response curve for PONV . A pooled analysis 
performed by Philip et al in 2000 demonstrated the dose-
response curve plateau well in 1946 postoperative patients. 
Their results showed that doses greater than 12.5 mg 
achieved no statistically significant increase in complete 
response.25 However, previous data also clearly demonstrate 
the emetogenic potential of chemotherapy to be much greater 
than that of PONV , based on dose requirements. In an early 
review of dolasetron, Balfour and Goa demonstrated 
a complete suppression of vomiting in 50%–70% of 
postoperative gynecology patients to doses as low as 
12.5–25 mg.9 However, patients receiving highly or 
moderately emetogenic chemotherapy require doses as high 
as 1.8 mg/kg to achieve a complete response (defined as no 
nausea, emesis, or rescue medication use in the first 24 hours) 
in 50% and 60%–80% of cases, respectively. An early study 
by Grote et al compared oral dolasetron doses of 25, 50, 
100, and 200 mg, which demonstrated response rates of 
44.7%, 71.3%, 73.2%, and 82.5%, respectively.26 Clearly the 
plateau effect is far less marked in the setting of moderately 
emetogenic chemotherapy.27 Radiation also appears to have 
a much higher emetogenic potential, because these patients 
showed complete response after 40 mg of dolasetron.9
Many comparative efficacy studies have been published 
on 5-HT3 receptor antagonists as each new generation of 
the class was developed. Most comparative investigations 
were based on ondansetron, the novel 5-HT3 receptor 
antagonist, though there are multiple pharmacologic 
differences in dolasetron compared with ondansetron. The 
most clinically notable difference is that the increased 
elimination half-life of hydrodolasetron, the active metabolite 
of dolasetron, is 2–3 times greater than for ondasetron. 
Further, hydrodolasetron has selective affinity for the 5-HT3 
receptor, whereas ondasetron also shows affinity for 5-HT4, 
5-HT1B, 5-HT1C, α1-adrenergic, and opioid µ receptors.8 This 
less selective affinity profile of ondansetron may result in an 
increased number of adverse or unintended drug reactions, 
though studies fail to demonstrate this effect clearly. Early 
results showed that 50 mg doses of dolasetron were as 
effective in preventing PONV as 4 mg of ondasetron, with 
71% and 64% showing a complete response, respectively.9 
However, based on the previously discussed more recent 
results by Philip et al, these higher doses may have been 
unnecessary to achieve the same results. Overall, multiple 
studies have at least demonstrated noninferiority of dolasetron 
compared with ondansetron.28–30
Comparative studies have also been completed against 
granisetron, another selective 5-HT3 receptor antagonist. In a 
small retrospective trial (n = 126), Hamadani et al2 evaluated 
antiemetic treatment failure, as defined by nausea or vomiting, 
in platinum-based chemotherapy comparing dolasetron with 
granisetron or ondansetron. All 5-HT3 receptor antagonists 
were given in conjunction with dexamethasone. In this 
study, no statistically significant difference in treatment 
failure was noted, which confirms previously published 
data demonstrating equivalent efficacy between dolasetron, 
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granisetron, and ondansetron.31,32 Therefore, the authors have 
concluded that the choice of antiemetic should be based on 
drug cost in the setting of both PONV and CINV .2,33 Steiner 
et al also found no clinically or statistically significant 
difference when granisetron was exchanged for dolasetron in 
the setting of CINV . This interchange resulted in no difference 
in patient satisfaction, therapeutic effectiveness, functional 
status, or nausea severity. However, they did note a substantial 
cost reduction when using dolasetron.34 However, when 
comparing dolasetron 100 mg orally with granisetron 2 mg 
orally in moderately or highly emetogenic chemotherapy, Tan 
et al found contradictory results in 2004. Their open-label 
study of 26 patients demonstrated a complete response rate of 
23.1% for the dolasetron group, while the granisetron group 
showed a complete response in 69.2%. When comparing the 
cost-effectiveness noted by the previous two authors, Tan 
et al found a seven-fold increase in rescue medication use 
in the dolasetron group, which would clearly reduce the cost 
benefit of dolasetron.35 However, due to the limited number 
of patients enrolled in this study and the contradictory results 
of previously published data, any evidence suggesting the 
superiority of granisetron over dolasetron is extremely 
limited.
Most recently, dolasetron has been compared head-
to-head with palonosetron, the newest drug of the class, 
approved by the US Food and Drug Administration 
in 2008. The earliest study comparing dolasetron with 
palonosetron was completed by Eisenberg et al in 2003. 
In this noninferiority study, two doses of palonosetron 
were compared with dolasetron in 592 patients undergoing 
moderately emetogenic chemotherapy. At 24 hours after 
chemotherapy (acute phase CINV), intravenous palonosetron 
0.25 mg was found have a higher complete response rate 
of 63.0% as compared with intravenous dolasetron 100 mg 
with a 52.9% complete response (P = 0.049). Likewise, at 
24–120 hours following chemotherapy (delayed CINV), 
palonosetron remained superior to dolasetron at 48.1% 
and 36.1%, respectively (P = 0.018).24 In a meta-analysis 
by Botrel et al in 2011, palonosetron was found to be 
superior to all other 5-HT3 receptor antagonists, including 
dolasetron, in preventing acute-phase and late-phase CINV in 
moderately or highly emetogenic chemotherapy.4 In another 
large, recent study published in 2011, Schwartzberg et al 
again compared palonosetron with all other 5-HT3 receptor 
antagonists in CINV , this time in the setting of triple therapy 
with dexamethasone and a NK1 receptor antagonist. In this 
retrospective study of 4552 patients, palonosetron showed 
a 17% lower risk of uncontrolled CINV during 5 days of 
highly emetogenic chemotherapy.36 Overall, the extremely 
long elimination half-life of palonosetron (40 hours) appears 
to give it a therapeutic advantage over dolasetron.24
A large area of recent interest in the dolasetron literature 
is its safety profile. As previously discussed, dolasetron has 
been shown to slow cardiac depolarization by blocking fast 
sodium channels, thereby reducing the maximum upstroke 
velocity of the action potential.12 This action potential effect 
causes changes in multiple electrocardiographic parameters, 
including heart rate, PR interval, QRS duration, and, at 
increased doses (2.4 mg/kg), the QTc interval. Until recently, 
these effects were thought to be limited and not clinically 
significant, with the exception of patients particularly suscep-
tible to these changes (including prolonged QTc at baseline, 
tachycardia in the setting of acute myocardial infarction).11 
Case reports have been published describing markedly 
adverse cardiovascular events resulting from both standard 
doses of dolasetron and intentional overdose. Rochford 
et al described the dramatic result of a patient ingesting 
2000 mg of dolasetron during an intentional overdose. She 
became markedly hemodynamically unstable, requiring 
vasopressors, and her electrocardiogram showed sinus 
rhythm with first-degree atrioventricular block, nonspecific 
intraventricular conduction delay, and a markedly prolonged 
QTc of 611 msec.37 This is obviously an extreme example of 
the adverse cardiovascular effects of dolasetron, but further 
significant events have been documented.
Higgins and Bunker have described an episode of 
intraoperative supraventricular tachycardia immediately 
following the administration of dolasetron 12.5 mg, 
a well established acceptable dose for PONV prophylaxis. 
An  otherwise  healthy  45-year-old  female  became 
hemodynamically unstable requiring treatment with 
amiodarone. Her symptoms resolved and, interestingly, 
her postoperative electrocardiogram showed no signs of 
prolonged intervals.38 Turner et al have also described an 
episode of acute QTc prolongation with progression to 
torsades de pointes and ultimately ventricular fibrillation one 
hour after dolasetron administration.39 Clearly, prolongation 
of QTc has been clearly associated with the development of 
torsades de pointes and potentially fatal arrhythmia, though 
only in 1% of these patients overall.40–42
Though these are profound examples of the cardiovascular 
effects of dolasetron, multiple studies consistently support 
cardiac conduction changes caused by dolasetron, though the 
clinical relevance of these changes is controversial. However, 
in 2010, the Food and Drug Administration issued a drug 
safety communication stating that dolasetron should no 
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longer be administered intravenously for the prevention of 
CINV . The basis of this statement is the compelling finding of 
a dose-dependent prolongation in QT, PR, and QRS intervals 
in recent studies and a report of a nearly three-fold increase 
in ventricular arrhythmia in patients treated with dolasetron, 
compared with ondansetron or granisetron, in one study.43,44 
This, in conjunction with previously documented findings, 
implies that dolasetron may be proarrhythmic because it 
prolongs the mean QT/QTc interval by .20 msec.45 These 
findings are only applicable to intravenous dolasetron used at 
the higher doses necessary for CINV , not the decreased dose 
needed for PONV prophylaxis. However, the Food and Drug 
Administration issued a similar warning in September 2011 
regarding ondansetron for patients with congenital long QT 
syndrome, which may further the evidence to suggest that 
this effect is not unique to dolasetron.46
Conclusion
Dolasetron represents an older type of 5HT3 receptor 
antagonist. Despite the fact that it has been present on the 
market for more than 20 years, it is still commonly used 
for prophylaxis and treatment of both PONV and CINV . Its 
effectiveness in the treatment of PONV and CINV is similar 
to other 5-HT3-antagonists, including ondansetron, topisetron, 
and granisetron, but it seems to be inferior when compared 
with newer, longer-acting 5-HT3-antagonists like palonosetron. 
The most commonly reported adverse reaction to dolasetron 
is headache, which is reported in up to 24% of patients. Other 
commonly reported events are mild, and include diarrhea, 
fatigue, and dizziness. The newer data provide evidence of 
significant cardiovascular events, in the form of QTc interval 
prolongation and subsequent arrhythmia associated with 
dolasetron administration, particularly in the higher dose 
ranges. In 2010, the Food and Drug Administration issued a 
drug safety communication stating that dolasetron should no 
longer be administered intravenously at higher doses for the 
prevention of CINV , though similar warnings now exist for 
ondansetron and granisetron for certain susceptible patient 
populations. Significant prolongation of the QTc interval 
seems to be common to all 5-HT3 antagonists (with the possible 
exception of palonosetron) and may represent a class effect 
for this group of drugs.4 Given the aforementioned findings, 
particular consideration should be given to certain patient 
populations prior to the administration of 5-HT3 receptor 
antagonists. Foremost, patients with a pre-existing history 
of widened QRS or prolonged QTc on electrocardiogram 
should be particularly concerning, especially at the higher 
doses required for CINV .
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